A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
2022-06-28
عنوان الدراسة
A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
داعم الدراسة
Boehringer Ingelheim
دواء الدراسة
BI 10773
رقم بروتوكول الدراسة
1245.25
حالة الدراسة
Completed
موقع الدراسة
KFMC
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。